Enliven Therapeutics to Host Webcast Conference Call to Discuss Phase 1 ELVN-001 Clinical Data Being Presented at EHA 2026 Congress
Enliven Therapeutics will host a webcast conference call on June 11, 2026, at 8:30 a.m. ET to discuss updated Phase 1 clinical data for ELVN-001. The data from the ENABLE trial in previously treated chronic myeloid leukemia (CML) patients will be presented orally at the EHA 2026 Congress in Stockholm later that day.
Key figures
- Drug Name
- ELVN-001
- Phase Of Trial
- Phase 1
- Nct id
- NCT05304377
- Conference
- EHA 2026 Congress
- Trial name
- ENABLE
- Presentation date
- June 11, 2026
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.